Beam Therapeutics (BEAM) Leases (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Leases for 7 consecutive years, with $100.7 million as the latest value for Q4 2025.
- Quarterly Leases fell 3.99% to $100.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100.7 million through Dec 2025, down 3.99% year-over-year, with the annual reading at $100.7 million for FY2025, 3.99% down from the prior year.
- Leases for Q4 2025 was $100.7 million at Beam Therapeutics, up from $97.0 million in the prior quarter.
- The five-year high for Leases was $118.5 million in Q4 2022, with the low at $13.6 million in Q2 2022.
- Average Leases over 5 years is $102.6 million, with a median of $105.4 million recorded in 2021.
- The sharpest move saw Leases soared 2442.71% in 2021, then crashed 87.09% in 2022.
- Over 5 years, Leases stood at $102.7 million in 2021, then rose by 15.38% to $118.5 million in 2022, then decreased by 4.78% to $112.8 million in 2023, then decreased by 7.07% to $104.9 million in 2024, then decreased by 3.99% to $100.7 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $100.7 million, $97.0 million, and $99.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.